1269294-26-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(thiophen-2-yl)pyrimidin-2-ol is used as a chemical intermediate for the synthesis of new drugs, leveraging its heterocyclic structure to explore its potential as a therapeutic agent. Its specific application reason is based on the hypothesis that its structural features may confer biological activities that could be beneficial in medicinal chemistry.
Further research and studies are essential to fully elucidate the potential uses and properties of 4-(thiophen-2-yl)pyrimidin-2-ol, as its exact applications and mechanisms of action are not yet fully understood. 4-(thiophen-2-yl)pyriMidin-2-ol's role in drug development may include targeting specific biological pathways or serving as a building block for more complex pharmaceutical agents.

Relevant academic research and scientific papers

PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS

The invention relates to pyrimidin-2-one compounds of general formula (I), in addition to the derivatives and tautomers of (I) and the physiologically acceptable salts of said compounds. In said formula: A represents linear or branched C3-C6 alkene, which can have a double bond or triple bond and/or a group Z, which is not adjacent to the nitrogen atom of the pyrimidinone ring and is selected from O, S, C(O), NR3, C(O)NR3, NR3C(O), OC(O) and C(O)O; B represents a group of formula (II), in which X stands for CH2 or N and Y stands for CH2 or CH2CH2, or X-Y can also jointly represent C=CH, C=CH-CH2 or CH-CH=CH; R1 and R 2 are defined as cited in the description and the claims; and Ar represents an optionally substituted aromatic group. The invention also relates to a pharmaceutical agent, containing at least one compound (I) and the tautomers, derivatives and/or acid addition salts of said compound, optionally together with physiologically acceptable carriers and/or auxiliary agents. The invention also relates to the use of compounds of formula (I), and their tautomers, derivatives and pharmacologically acceptable acid addition salts for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor ligands.